Chad Patel’s Post

The latest edition of  ZoomRx's Oncology Manufacturer Perception Report is out! ZoomRx Manufacturer Perception Tracking tracks the perception of ~1000 HCPs from the US and EU across 12 key dimensions for 30+ manufacturers in 5 key therapeutic areas. Oncology Perception Report Highlights: 1. Roche/Genentech Reigns Supreme: Leading with 60% of Oncologists' top mentions, thanks to its history and portfolio awareness. 2. AstraZeneca's Close Second: AstraZeneca follows closely behind, driven by its impressive portfolio and recent innovations. 3. Room for Challengers: There's no single dominant player across all metrics, presenting a significant growth opportunity for challengers to establish their presence in the oncology field. 📩 For an in-depth view, contact Karni Medh (karni.medh@zoomrx.com) or Manoj Hariharaputhiran (manoj.hariharaputhiran@zoomrx.com). #biopharma #pharmaceuticals #lifesciencesindustry #oncology

Hemogenyx Pharmaceuticals has made major progress in its efforts to get its CAR-T clinic approved by the FDA. Hemogenyx is the first company to receive the FDA's go-ahead to move forward with its plan to address the agency's concerns regarding the safety and efficacy of CAR-T treatments. This is major news for Hemogenyx and a major step forward for the biotech industry as a whole. CAR-T therapies have the potential to revolutionize cancer treatment, and Hemogenyx is leading the charge. The company is committed to ensuring that its CAR-T treatments are safe and effective for patients. Hemogenyx's efforts are a huge success for the biotech industry, and could potentially pave the way for other companies to follow suit. With Hemogenyx's success, more patients may soon have access to the innovative CAR-T treatments that could potentially save their lives. #CAR-T #Biotech #CancerTreatment #Biotech #BioPharma

🌐 𝗧𝗼𝗽 𝟭𝟱 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗯𝘆 𝗪𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲 𝗦𝗮𝗹𝗲𝘀 𝗶𝗻 𝗤𝟭 𝟮𝟬𝟮𝟰 Maven Bio's latest research reveals the leading oncology medicines and their sales performance in Q1 2024. 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: - Keytruda (Merck): $6.95B, +24% growth - Darzalex (Johnson & Johnson): $2.69B, +21% growth - Opdivo (Bristol Myers Squibb): $2.08B, -2% growth 𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗴𝗿𝗼𝘄𝘁𝗵 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗲𝗿𝘀: - Verzenio (Eli Lilly and Company): +40% - Imfinzi (AstraZeneca): +33% - Enhertu (AstraZeneca/Daiichi Sankyo US): +65% These figures reflect significant advancements and investments in the oncology sector, driving improved patient outcomes and innovations in cancer treatment. #Oncology #Pharmaceuticals #Healthcare #CancerResearch #Biopharma

Revolutionizing Cancer Treatment: The Injectable Cytotoxic Drugs Making Waves According to the assessment study by Growth Plus Reports, the global injectable cytotoxic drugs market was valued at 𝐔𝐒$ 𝟏𝟖.𝟒𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐 and is expected to register a revenue 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟔.𝟕% to reach 𝐔𝐒$ 𝟑𝟑.𝟎𝟖 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟏. Get free sample PDF now: https://lnkd.in/dC7etm9g Top companies:           Johnson & Johnson Sanofi Eli Lilly and Company Bristol Myers Squibb F. Hoffmann-La Roche Ltd Novartis Pfizer Merck Group Amgen #CytotoxicDrugs #InjectableMedications #OncologyPharmaceuticals #CancerTreatment #Chemotherapy #AntineoplasticDrugs #CancerTherapy #OncologyMedications #PharmaceuticalIndustry #MedicalResearch #HealthcareInnovation #DrugDevelopment #PrecisionMedicine #OncologyCare #CancerResearchTop

✨ Unlocking the Future of Precision Oncology: Navigating the Tumor-Agnostic Treatment Landscape With 7 FDA approvals granted and over a similar number being investigated, tumor-agnostic therapies are shaking up the oncology arena, transcending traditional boundaries. In the attached review, we delve into the pivotal role of tumor-agnostic drug development in the realm of precision oncology, including key regulatory, clinical, and commercial considerations. Comment below 👇 to get a copy of the full report. #precisiononcology #tumoragnostic #oncology #pharma #pharmaceuticals #biotech #biomarkers #competitiveintelligence #atacanagroup

Novartis' breakthrough with Pluvicto has triggered a wave of mergers and acquisitions in the radiopharmaceuticals sector among major pharmaceutical companies. These targeted treatments deliver radiation directly to cancer cells while preserving healthy tissue. However, challenges like scarcity of radioactive materials and quick administration needs persist. According to RBC Capital Markets, the radiopharmaceuticals market is expected to grow to $25 billion, with Novartis leading the way. Despite the positive forecast, competition from other targeted cancer therapies is a factor that Big Pharma companies must take into account. Check out at https://lnkd.in/gDg9XAjd Source: Investor's Business Daily #Novartis #Pluvicto #radiopharmaceuticals #Elililly #BMS #BristolMyersSquibb #M&A #mergersandacquisitions #cancer #RBCCapitalMarkets #healthcareindustry #targetedtherapy #oncology #medicalinnovation #pharmaceuticals #cancertreatment #radiationtherapy #BigPharma #competition #medicaltechnology #drugdevelopment #healthcaremarket #ISPOR #ISPORUS

Are you handling the increased complexity of oncology forecasts? The oncology space is constantly evolving and, as a result, so are your forecasts. Greater efficacy – with improved disease progression – and greater control of a product’s use across different lines of therapy are just two examples of current complexities of forecasting in the oncology space. The question is: are you accounting for them in your forecasts? Read more about these new complexities here: https://lnkd.in/etM8tddP Editor: Sam Johnson, director of research and development #pharma #oncology #forecasting 

Thoughts on this? >> Sanofi spotlights early-stage cancer assets, counts on grandfather clause on Biosecure >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #productmarketing #healthcare

Keep a finger on the pulse 🩺 BiopharmIQ will share weekly updates on recent + YTD M&A activity.. If you want access to the historical M&A data reach out: - Disease areas of acq'd - Stage lead asset of acq'd - Tech/modality of acq'd company

✨ Exciting News in #Oncology Treatment! ✨ AbbVie's monoclonal antibody Elahere has received full FDA approval for certain types of #ovarian #cancer treatment. 🎗️ 🔍 #Elahere, an antibody-drug conjugate targeting folate receptor alpha, is now approved for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal #cancer in adult patients after one to three prior systemic treatments. 🚀 #AbbVie's acquisition of ImmunoGen, Inc. paved the way for Elahere's development, culminating in this significant milestone. The Phase III MIRASOL trial showcased its efficacy, demonstrating a 35% reduction in the risk of tumor progression compared to chemotherapy, along with meeting key secondary endpoints. 💡 Despite competition, Elahere's first-to-market advantage positions it strongly in the pharmaceutical landscape. GlobalData Healthcare's forecast suggests substantial revenue potential, projecting $2.8bn in 2029. Connect, Repost & Follow for more info on the pharmaceutical industry 🌍 #pharma #pharmaceutical #pharmaindustry #europe #healthcare #fda #ema #pharmacy #ra #qa #pharmaceuticalindustry #medicine